Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JANXNASDAQ:SAGENASDAQ:SDGRNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJANXJanux Therapeutics$33.20+2.0%$29.83$22.52▼$71.71$1.96B3.27848,751 shs938,891 shsSAGESage Therapeutics$7.29-4.1%$7.54$4.62▼$14.56$448.20M0.481.22 million shs1.33 million shsSDGRSchrödinger$25.63-0.6%$22.23$16.60▼$28.47$1.87B1.77840,173 shs703,589 shsTARSTarsus Pharmaceuticals$51.91+2.0%$47.73$20.08▼$57.28$1.99B0.94693,568 shs598,277 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJANXJanux Therapeutics+0.99%+8.46%+11.86%-23.43%-41.96%SAGESage Therapeutics-2.19%-1.04%-8.21%+3.68%-46.40%SDGRSchrödinger+0.12%-0.81%+29.16%+3.29%+5.48%TARSTarsus Pharmaceuticals+2.37%+2.95%-1.62%-4.09%+58.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJANXJanux Therapeutics2.9925 of 5 stars3.52.00.00.02.95.00.0SAGESage Therapeutics3.7265 of 5 stars3.02.00.04.01.81.71.3SDGRSchrödinger2.2747 of 5 stars3.51.00.00.02.72.50.6TARSTarsus Pharmaceuticals1.3692 of 5 stars2.50.00.00.03.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJANXJanux Therapeutics 3.09Buy$95.25186.90% UpsideSAGESage Therapeutics 2.00Hold$8.8120.88% UpsideSDGRSchrödinger 3.00Buy$33.0028.76% UpsideTARSTarsus Pharmaceuticals 3.00Buy$63.6722.65% UpsideCurrent Analyst Ratings BreakdownLatest SAGE, TARS, JANX, and SDGR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/16/2025SDGRSchrödingerKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $32.003/11/2025SAGESage TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform$5.003/6/2025TARSTarsus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $58.003/3/2025JANXJanux TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/28/2025JANXJanux TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.002/28/2025JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $76.002/27/2025SDGRSchrödingerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.002/26/2025TARSTarsus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$62.00 ➝ $60.002/26/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $73.002/24/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $78.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJANXJanux Therapeutics$10.59M185.33N/AN/A$7.46 per share4.45SAGESage Therapeutics$41.24M10.87N/AN/A$7.56 per share0.96SDGRSchrödinger$207.54M9.02$0.68 per share37.42$7.60 per share3.37TARSTarsus Pharmaceuticals$182.95M10.89N/AN/A$5.95 per share8.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJANXJanux Therapeutics-$58.29M-$1.28N/AN/AN/A-463.91%-10.47%-9.86%5/6/2025 (Estimated)SAGESage Therapeutics-$400.67M-$6.59N/AN/AN/A-971.50%-68.18%-60.84%N/ASDGRSchrödinger$40.72M-$2.57N/AN/AN/A-91.84%-35.77%-24.51%5/7/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$3.10N/AN/AN/A-103.64%-55.86%-39.28%5/6/2025 (Estimated)Latest SAGE, TARS, JANX, and SDGR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/7/2025Q1 2025SDGRSchrödinger-$0.81N/AN/AN/A$54.60 millionN/A5/6/2025Q1 2025JANXJanux Therapeutics-$0.42N/AN/AN/A$0.59 millionN/A4/29/2025Q1 2025SAGESage Therapeutics-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/A2/26/2025Q4 2024SDGRSchrödinger-$0.35-$0.55-$0.20-$0.55$83.20 million$88.32 million2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 million2/11/2025Q4 2024SAGESage Therapeutics-$1.54-$1.56-$0.02-$1.56$14.37 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJANXJanux TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ASDGRSchrödingerN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJANXJanux TherapeuticsN/A38.8038.80SAGESage TherapeuticsN/A7.427.42SDGRSchrödingerN/A4.114.11TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJANXJanux Therapeutics75.39%SAGESage Therapeutics99.22%SDGRSchrödinger79.05%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipJANXJanux Therapeutics29.40%SAGESage Therapeutics5.50%SDGRSchrödinger8.60%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJANXJanux Therapeutics3059.11 million37.05 millionOptionableSAGESage Therapeutics69061.48 million58.10 millionOptionableSDGRSchrödinger79073.04 million66.59 millionOptionableTARSTarsus Pharmaceuticals5038.38 million35.07 millionOptionableSAGE, TARS, JANX, and SDGR HeadlinesRecent News About These CompaniesWall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?April 30 at 10:55 AM | zacks.com20,811 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Artia Global Partners LPApril 29 at 7:00 AM | marketbeat.comBarclays PLC Lowers Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 29 at 3:50 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by BrokeragesApril 29 at 2:37 AM | marketbeat.comBoothbay Fund Management LLC Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 6:46 AM | marketbeat.comGilder Gagnon Howe & Co. LLC Buys 397,190 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 6:29 AM | marketbeat.comLord Abbett & CO. LLC Increases Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 5:56 AM | marketbeat.comLPL Financial LLC Sells 5,125 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 3:09 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Wells Fargo & Company MNApril 26, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Canada Pension Plan Investment BoardApril 25, 2025 | marketbeat.comTarsus Pharmaceuticals to Host Live Webcast for Q1 2025 Financial Results and Corporate UpdateApril 24, 2025 | quiverquant.comTarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025April 24, 2025 | globenewswire.comSilverarc Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 24, 2025 | marketbeat.comDiadema Partners LP Makes New $3.32 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 24, 2025 | marketbeat.comTarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meetingApril 24, 2025 | markets.businessinsider.comRock Springs Capital Management LP Invests $6.14 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 23, 2025 | marketbeat.comTarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual MeetingApril 22, 2025 | globenewswire.comOC Drugmakers Grow Workforce 7%April 21, 2025 | ocbj.comAlpha DNA Investment Management LLC Purchases New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 21, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co.April 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAGE, TARS, JANX, and SDGR Company DescriptionsJanux Therapeutics NASDAQ:JANX$33.20 +0.65 (+2.00%) As of 04:00 PM EasternJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Sage Therapeutics NASDAQ:SAGE$7.29 -0.31 (-4.08%) As of 04:00 PM EasternSage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Schrödinger NASDAQ:SDGR$25.63 -0.15 (-0.58%) As of 04:00 PM EasternSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Tarsus Pharmaceuticals NASDAQ:TARS$51.91 +1.01 (+1.98%) As of 04:00 PM EasternTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
